Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Target Price at $15.72

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given a consensus rating of “Buy” by the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $15.72.

A number of equities analysts have recently weighed in on VYGR shares. Cantor Fitzgerald started coverage on Voyager Therapeutics in a report on Friday, January 10th. They set an “overweight” rating and a $5.73 price target for the company. Citigroup started coverage on Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $9.00 price target (down from $11.00) on shares of Voyager Therapeutics in a report on Tuesday, February 11th. Canaccord Genuity Group restated a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th.

Insider Activity

In other news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 10,778 shares of company stock worth $58,548. 4.53% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in VYGR. Erste Asset Management GmbH acquired a new stake in shares of Voyager Therapeutics during the 3rd quarter worth about $6,192,000. Vestal Point Capital LP raised its position in shares of Voyager Therapeutics by 151.0% during the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after acquiring an additional 740,000 shares in the last quarter. Farallon Capital Management LLC raised its position in shares of Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock worth $14,576,000 after acquiring an additional 278,700 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Voyager Therapeutics by 24.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock worth $7,828,000 after acquiring an additional 275,571 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Voyager Therapeutics during the 4th quarter worth about $746,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Trading Up 2.9 %

NASDAQ VYGR opened at $4.26 on Friday. The stock has a market cap of $232.71 million, a PE ratio of 6.00 and a beta of 0.99. Voyager Therapeutics has a twelve month low of $3.80 and a twelve month high of $10.66. The stock has a fifty day simple moving average of $5.01 and a 200-day simple moving average of $5.92.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.